Key facts
- Genesis Medical’s last known valuation is $10.0M (May 2025).
- It has raised $4.3M; the latest was Seed Round ($5.0M) in Jun 2025.
- Notable investors include Innovation Authority, Arieli Innovate, EthAum, GDG Media Groupe, Gideon Dover — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Genesis Medical
- ·The full record, as it builds
Funding rounds
No funding rounds for Genesis Medical are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Genesis Medical
Developer of AI-powered cancer early detection platforms designed to improve diagnostic accuracy. The company's platform employs a clinically validated, explainable methodology that mimics expert physician reasoning, achieving accuracy with near-zero false positives, reducing liability and workload for radiologists, supporting risk-population screening programs, enabling early detection of nodules, and providing healthcare with reliable tools to enhance cancer screening and diagnosis efficiency.
- Sector
- Healthcare
- HQ
- Herzeliya, Israel
- Founded
- 2022
- Employees
- 6
- Website
- genesis-medical.ai/
- Ownership
- Privately Held (backing)
Genesis Medical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Genesis Medical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Genesis Medical in its N-PORT filings yet. We sweep new filings monthly.